In order to participate in this study, you must be able to speak and read Dutch fluently. 

The goal of this study is to evaluate how safe, tolerable and effective the new drug IBC-Ab002 is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the new drug IBC-Ab002 with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’). The study drug is administered through an intravenous (IV) injection.

Aging increases the risk of developing Alzheimer’s disease, and it also affects the progression of Alzheimer’s disease. IBC-Ab002 responds to this by slightly modifying the development of the immune system that is associated with aging. This should cause more immune cells to be produced by the body, resulting in more nerve cells in the brain being preserved (which normally decrease in people with Alzheimer’s disease), and improve cognitive functioning.

This study is performed in 2 parts called part A and part B. You will receive the study drug 4 times; a single dose in Part A followed by 3 doses in Part B.

The study period lasts approximately 56 weeks. You and your study partner, someone who knows you well and can answer questions about your daily functioning, will visit the research center and/or hospital about 23 times. The length of a visit is not always the same because the same checks are not done at each visit. Some of these visits during the study may last up to 6 hours, others up to 3.5 hours. You will be asked to stay 1 night in the study clinic only for the 1st administration of the study drug. You will also have several phone calls. A telephone call will last approximately 15 minutes. This research takes place in Amsterdam.

This research is commissioned by Immunobrain Checkpoint.

You always decide whether you participate in a study. Participation is always voluntary.

1. You apply via the online form, this is non-binding.
2. After application, you are phoned, this is also an opportunity for you to ask questions. During this conversation, we also ask some questions to see whether you are eligible to participate in research. After this conversation, you determine whether you want to progress to step 3.
3. You receive an email with the request to sign a document in which you give permission to retrieve your medical data.
4. When your medical data shows that you meet the requirements to participate in the study, you are invited to a meeting at our location. During this meeting, you receive information and have the opportunity to ask questions, before you decide to participate in research.
5. If you decide to participate in the study, you sign a form and will start the study within several weeks.

1. You always come first – everything we do revolves around you.
2. Experienced team of doctors, neuropsychologists, and nurses.
3. Open and homely atmosphere – this will make you feel relaxed and right at home.
4. Clarity – expert in medicine research which is why you will be well informed during all steps of the process and can always come to us for questions.
5. Always nearby – 3 locations spread through the Netherlands.

• You may experience benefits from a new treatment.
• You will be monitored by a specialized team of healthcare professionals. They can give you advice and monitor whether there is a change in your daily functioning.
• You make a meaningful contribution to a future without Alzheimer’s.
• You contribute to the advancement of science.

• You can participate when:
  • You have early stage Alzheimer’s disease
  • You are between 50 and 80 years old
  • You have someone close to you/a caregiver who can accompany you during the visits to the research center and can answer questions about your health and functioning, among other things.

  Are you unsure whether you meet these requirements? Then you can always apply. We will then check together whether you are suitable to participate.